Answers are grounded in this paper and cite their sources.
Background COVID-19 is arguably the number-one public health concern worldwide, and efforts are now escalating to control its spread. Objective In this study, we undertake a meta-analysis to estimate the global and regional anti-SARS-CoV-2 seroprevalence rates in humans and assess whether seroprevalence associates with geographical, climatic and socio-demographic factors. Data sources We systematically reviewed PubMed, Scopus, Embase, medRxiv and bioRxiv for peer-reviewed articles or preprints (up to 14 August 2020). Study eligibility criteria Population-based studies describing prevalence of anti-SARS-CoV-2 serum antibodies in general people. Participants general people who were tested for prevalence of anti-SARS-CoV-2 serum antibodies. Interventions There were no interventions. Methods We used random-effects model to estimate pooled seroprevalence, and then extrapolated these findings to the global population (for 2020). Sub-group and meta-regression analyses explored potential sources of heterogeneity in the data and relationships between seroprevalence and socio-demographic, geographical and climatic factors. Results In total, 47 serological studies involving 399,265 people from 23 countries met the inclusion criteria. The pooled seroprevalence of SARS-CoV-2 in general people was estimated at 3.38% (95% CI, 3.05%–3.72%; 15,879/399,265). On a regional basis, we determined seroprevalence estimates of 5.27% (3.97–6.57%) in Northern Europe; 4.41% (2.20–6.61%) in Southern Europe; 4.41% (3.03– 5.79%) in North America; 3.17% (1.96–4.38%) in Western Europe; 2.02% (1.56–2.49%) in the Eastern Asia; and 1.45% (0.95–1.94%) in South America. Extrapolating to the 2020 world population, we estimated that 263,565,606 individuals had been exposed or infected with SARS-CoV-2 at the first wave of the pandemic. A significantly higher seroprevalence was related to higher income levels and human development indices, higher geographical latitudes and lower mean environmental temperatures. Interpretation This study reinforces that SARS-CoV-2 infection is a very rapidly-spreading communicable disease and calls for routine surveys to constantly monitor temporal changes in seroprevalence around the globe.
No takes yet. Share an insight, caveat, or question.
Rostami et al. (2020) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: